{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T13:17:04Z","timestamp":1777295824224,"version":"3.51.4"},"reference-count":35,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100007128","name":"Natural Science Foundation of Shaanxi Province","doi-asserted-by":"crossref","award":["2012JQ4025"],"award-info":[{"award-number":["2012JQ4025"]}],"id":[{"id":"10.13039\/501100007128","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100007128","name":"Natural Science Foundation of Shaanxi Province","doi-asserted-by":"crossref","award":["2013KTCL03-02"],"award-info":[{"award-number":["2013KTCL03-02"]}],"id":[{"id":"10.13039\/501100007128","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2014M552458"],"award-info":[{"award-number":["2014M552458"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","cancerletters.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1016\/j.canlet.2014.10.033","type":"journal-article","created":{"date-parts":[[2014,10,31]],"date-time":"2014-10-31T16:06:14Z","timestamp":1414771574000},"page":"791-799","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"PB","title":["Divalproex sodium enhances the anti-leukemic effects of imatinib in chronic myeloid leukemia cells partly through SIRT1"],"prefix":"10.1016","volume":"356","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9972-0168","authenticated-orcid":false,"given":"Weirong","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianfeng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanxiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaofeng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanhao","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tingting","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiye","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rong","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2014.10.033_bib0010","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1002\/(SICI)1096-8652(199912)62:4<212::AID-AJH3>3.0.CO;2-S","article-title":"Morphological and functional characteristics of short-term and long-term bone marrow cultures in chronic myelogenous leukemia","volume":"62","author":"Budak-Alpdogan","year":"1999","journal-title":"Am. J. Hematol"},{"key":"10.1016\/j.canlet.2014.10.033_bib0015","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/1756-8722-3-47","article-title":"First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib","volume":"3","author":"Wei","year":"2010","journal-title":"J. Hematol. Oncol"},{"key":"10.1016\/j.canlet.2014.10.033_bib0020","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI571 cancer therapy caused by BCR-ABL gene mutation or amplification","volume":"293","author":"Gorre","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.canlet.2014.10.033_bib0025","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1535-6108(02)00096-X","article-title":"Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia","volume":"2","author":"Shah","year":"2002","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2014.10.033_bib0030","doi-asserted-by":"crossref","first-page":"3236","DOI":"10.1182\/blood-2002-08-2675","article-title":"Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells","volume":"101","author":"Nimmanapalli","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2014.10.033_bib0035","first-page":"5126","article-title":"Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells","volume":"63","author":"Nimmanapalli","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.canlet.2014.10.033_bib0040","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0065-230X(04)91004-4","article-title":"Histone deacetylase inhibitors","volume":"91","author":"Marks","year":"2004","journal-title":"Adv. Cancer Res"},{"key":"10.1016\/j.canlet.2014.10.033_bib0045","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.2174\/092986711795471284","article-title":"Developing histone deacetylase inhibitors as anti-cancer therapeutics","volume":"18","author":"Venugopal","year":"2011","journal-title":"Curr. Med. Chem"},{"key":"10.1016\/j.canlet.2014.10.033_bib0050","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1158\/1078-0432.CCR-13-1576","article-title":"Reducing TNF receptor 2\u2009+\u2009regulatory T cells via the combined action of azacitidine and the HDAC inhibitor, panobinostat for clinical benefit in acute myeloid leukemia patients","volume":"20","author":"Govindaraj","year":"2014","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.canlet.2014.10.033_bib0055","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1200\/JCO.2006.10.2434","article-title":"Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma","volume":"25","author":"Olsen","year":"2007","journal-title":"J. Clin. Oncol"},{"key":"10.1016\/j.canlet.2014.10.033_bib0060","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.2174\/138161207782360528","article-title":"Valproic acid as anti-cancer drug","volume":"13","author":"Michaelis","year":"2007","journal-title":"Curr. Pharm. Des"},{"key":"10.1016\/j.canlet.2014.10.033_bib0065","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1002\/cncr.23433","article-title":"Valproic acid for the treatment of myeloid malignancies","volume":"112","author":"Shah","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.canlet.2014.10.033_bib0070","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S1525-5050(02)00028-8","article-title":"Concomitant use of divalproex sodium and lamotrigine in developmentally disabled patients with epilepsy: a retrospective evaluation of efficacy and tolerability","volume":"3","author":"Maganti","year":"2002","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.canlet.2014.10.033_bib0075","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1158\/0008-5472.CAN-08-3365","article-title":"The critical role of the class III histone deacetylase SIRT1 in cancer","volume":"69","author":"Liu","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.canlet.2014.10.033_bib0080","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1124\/jpet.107.124461","article-title":"Bcr-Abl-independent imatinib-resistant K562 cells show aberrant protein acetylation and increased sensitivity to histone deacetylase inhibitors","volume":"322","author":"Lee","year":"2007","journal-title":"J. Pharmacol. Exp. Ther"},{"key":"10.1016\/j.canlet.2014.10.033_bib0085","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1182\/blood-2011-06-361691","article-title":"Activation of stress response gene SIRT1 by BCR-ABL promotes leukemogenesis","volume":"119","author":"Yuan","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2014.10.033_bib0090","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1016\/j.leukres.2013.08.019","article-title":"CUEDC2 sensitizes chronic myeloid leukemic cells to imatinib treatment","volume":"37","author":"Zhang","year":"2013","journal-title":"Leuk. Res"},{"key":"10.1016\/j.canlet.2014.10.033_bib0095","first-page":"337","article-title":"Establishment of an imatinib resistant cell line K562\/G01 and its characterization","volume":"25","author":"Qi","year":"2004","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"10.1016\/j.canlet.2014.10.033_bib0100","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/bjc.1991.7","article-title":"Characterisation of adriamycin- and amsacrine-resistant human leukaemic T cell lines","volume":"63","author":"Snow","year":"1991","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.canlet.2014.10.033_bib0105","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s10495-013-0833-7","article-title":"SIRT1 inhibits TNF-\u03b1-induced apoptosis of vascular adventitial fibroblasts partly through the deacetylation of FoxO1","volume":"18","author":"Wang","year":"2013","journal-title":"Apoptosis"},{"key":"10.1016\/j.canlet.2014.10.033_bib0110","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.ccr.2010.03.011","article-title":"Effective targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate","volume":"17","author":"Zhang","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2014.10.033_bib0115","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1365-2141.2008.07426.x","article-title":"Valproate synergizes with purine nucleoside analogues to induce apoptosis of B-chronic lymphocytic leukaemia cells","volume":"144","author":"Bouzar","year":"2009","journal-title":"Br. J. Haematol"},{"key":"10.1016\/j.canlet.2014.10.033_bib0120","first-page":"248","article-title":"The effects of the histone deacetylase inhibitor valproic acid on cell cycle, growth suppression and apoptosis in multiple myeloma","volume":"91","author":"Kaiser","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.canlet.2014.10.033_bib0125","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.exphem.2009.10.005","article-title":"Effect of imatinib on the signal transduction cascade regulating telomerase activity in K562 (BCR-ABL-positive) cells sensitive and resistant to imatinib","volume":"38","author":"Mor-Tzuntz","year":"2010","journal-title":"Exp. Hematol"},{"key":"10.1016\/j.canlet.2014.10.033_bib0130","doi-asserted-by":"crossref","first-page":"8912","DOI":"10.1158\/0008-5472.CAN-05-0076","article-title":"Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia","volume":"65","author":"Barnes","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.canlet.2014.10.033_bib0135","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.blre.2011.09.001","article-title":"Managing resistance in chronic myeloid leukemia","volume":"25","author":"Roychowdhury","year":"2011","journal-title":"Blood Rev"},{"key":"10.1016\/j.canlet.2014.10.033_bib0140","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1002\/cncr.21725","article-title":"Valproate enhances imatinib-induced growth arrest and apoptosis in chronic myeloid leukemia cells","volume":"106","author":"Morotti","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.canlet.2014.10.033_bib0145","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0092-8674(00)81277-5","article-title":"STATs: signal transducers and activators of transcription","volume":"84","author":"Ihle","year":"1996","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2014.10.033_bib0150","first-page":"247","article-title":"Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia","volume":"13","author":"Shuai","year":"1996","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2014.10.033_bib0155","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/leu.2013.351","article-title":"PAK-dependent STAT5 serine phosphorylation is required for BCR-ABL-induced leukemogenesis","volume":"28","author":"Berger","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.canlet.2014.10.033_bib0160","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1158\/0008-5472.CAN-03-1484","article-title":"Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia","volume":"64","author":"Donato","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.canlet.2014.10.033_bib0165","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3009073","article-title":"A therapeutically targetable mechanism of BCR-ABL-independent imatinib resistance in chronic myeloid leukemia","volume":"6","author":"Ma","year":"2014","journal-title":"Sci. Transl. Med"},{"key":"10.1016\/j.canlet.2014.10.033_bib0170","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1158\/1078-0432.CCR-12-2799","article-title":"PLK1 inhibitors synergistically potentiate HDAC inhibitor lethality in imatinib mesylate-sensitive or -resistant BCR\/ABL+ leukemia cells in vitro and in vivo","volume":"19","author":"Dasmahapatra","year":"2013","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.canlet.2014.10.033_bib0175","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.ccr.2011.12.020","article-title":"Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with imatinib","volume":"21","author":"Li","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2014.10.033_bib0180","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1158\/0008-5472.CAN-10-4452","article-title":"Nicotinamide blocks proliferation and induces apoptosis of chronic lymphocytic leukemia cells through activation of the p53\/miR-34a\/SIRT1 tumor suppressor network","volume":"71","author":"Audrito","year":"2011","journal-title":"Cancer Res"}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383514006326?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383514006326?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,27]],"date-time":"2018-09-27T22:55:29Z","timestamp":1538088929000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383514006326"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["S0304383514006326"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2014.10.033","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2015,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Divalproex sodium enhances the anti-leukemic effects of imatinib in chronic myeloid leukemia cells partly through SIRT1","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2014.10.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}